Weiss Ratings Reaffirms Hold (C) Rating for TransMedics Group (NASDAQ:TMDX)

Key Points

• Weiss Ratings has reaffirmed a "hold (c)" rating for TransMedics Group (NASDAQ:TMDX), while other analysts have recently increased their target prices, with Oppenheimer setting it at $150.00.
• TransMedics Group reported an EPS of $0.92 for the last quarter, significantly exceeding analysts' expectations and representing a 37.7% increase in revenue year-over-year.
• Institutional investors own 99.67% of TransMedics Group's stock, with hedge funds significantly increasing their positions in recent months.

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "hold (c)" rating reissued by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

A number of other research analysts have also recently issued reports on TMDX. Oppenheimer increased their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Morgan Stanley increased their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Canaccord Genuity Group increased their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Evercore ISI assumed coverage on shares of TransMedics Group in a report on Tuesday, September 16th. They issued an "outperform" rating and a $155.00 target price for the company. Finally, Zacks Research cut shares of TransMedics Group from a "strong-buy" rating to a "hold" rating in a report on Monday. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $125.40.

TransMedics Group Stock Performance

Shares of TMDX stock traded up $2.88 during mid-day trading on Wednesday, hitting $118.06. The stock had a trading volume of 547,397 shares, compared to its average volume of 905,958. The firm has a market cap of $4.02 billion, a PE ratio of 61.17 and a beta of 2.08. The company's 50-day simple moving average is $117.60 and its 200-day simple moving average is $111.28. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $145.50.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm's revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that TransMedics Group will post 1 earnings per share for the current year.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock valued at $209,448,000 after purchasing an additional 2,209,996 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of TransMedics Group by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 804,650 shares of the company's stock valued at $107,845,000 after purchasing an additional 11,241 shares during the last quarter. Driehaus Capital Management LLC boosted its holdings in shares of TransMedics Group by 2.4% in the 1st quarter. Driehaus Capital Management LLC now owns 778,754 shares of the company's stock valued at $52,395,000 after purchasing an additional 17,913 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of TransMedics Group by 258.7% during the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company's stock valued at $73,275,000 after acquiring an additional 394,340 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock valued at $34,145,000 after acquiring an additional 86,721 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.